News
Press Release | December 15, 2022
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
Press Release | December 12, 2022
Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA
Press Release | December 12, 2022
Freenome Presents Research Highlighting The Promise of Identifying Drug-Response Biomarker for DLBCL Patients
Press Release | December 8, 2022
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Press Release | December 8, 2022
Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™
Press Release | November 24, 2022
Proud to congratulate ImCheck’s scientific founder, Prof. Daniel Olive, on his election as President of the French Society of Immunology
Press Release | November 15, 2022
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers
News | November 14, 2022
Ionis, Metagenomi pen Big Pharma-sized genetic target pact that could total almost $3B
Press Release | November 11, 2022
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
Press Release | November 7, 2022
Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Press Release | November 7, 2022
Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics
Press Release | November 1, 2022
Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target
Press Release | October 11, 2022
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
Press Release | October 3, 2022
Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies
Press Release | September 10, 2022
ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
Press Release | September 1, 2022
Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
1
2